Related Experiment Video
Updated: Jan 29, 2026
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Analysis of Periostin, TGF-β, and SLUG Expression in Inflammatory Bowel Disease in Pediatric Patients and Their
Patrycja Sputa-Grzegrzolka1, Anna Socha-Banasiak2, Aleksandra Piotrowska3
1Division of Anatomy, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Insights
Periostin, TGF-β, and SLUG are elevated in pediatric inflammatory bowel disease (pIBD). Periostin may play a role in inflammation and fibrosis, suggesting a potential therapeutic target for pIBD.
Area of Science:
- Gastroenterology
- Molecular Biology
- Pediatric Medicine
Background:
- Pediatric inflammatory bowel disease (pIBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), involves chronic intestinal inflammation and fibrosis.
- Identifying key molecular mediators is crucial for effective pIBD management and therapeutic development.
Purpose of the Study:
- To investigate the expression of periostin, TGF-β, and SLUG in pediatric IBD patients.
- To evaluate the association of these markers with intestinal inflammation, fibrosis, and mucosal healing.
- To explore their potential as biomarkers for pIBD activity and therapeutic targets.
Main Methods:
- Immunohistochemical analysis of intestinal biopsies from 33 pediatric IBD patients (11 CD, 22 UC) and 10 controls.
- Quantitative PCR to assess POSTN, TGF-β1, and SNAI2 gene expression in a subset of patients and controls.
- Correlation analysis with clinical disease activity indices (PCDAI, PUCAI) and fecal calprotectin levels.
Main Results:
- Periostin, TGF-β, and SLUG expression were significantly upregulated in pIBD patients compared to healthy controls.
- Higher periostin levels were observed in CD patients relative to UC patients.
- All three markers showed positive correlations at both mRNA and protein levels, with periostin inversely correlating with disease activity scores.
Conclusions:
- Periostin, TGF-β, and SLUG may serve as valuable biomarkers for assessing pIBD activity.
- Periostin's role in mediating inflammation and fibrosis suggests it could be a potential therapeutic target for pIBD.
- The inverse correlation of periostin with disease activity warrants further investigation into its therapeutic potential.
Abstract:
Background: Pediatric inflammatory bowel disease (pIBD), including Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic intestinal inflammation and fibrosis. Identifying molecular mediators involved in inflammation and tissue repair is critical for improving disease management. Objective: To examine the expression of periostin, TGF-β, and SLUG in pIBD and assess their potential roles in intestinal inflammation, fibrosis, and mucosal healing. Methods: Intestinal biopsies from 33 pediatric patients (11 CD, 22 UC) and 10 healthy controls were analyzed immunohistochemically. Quantitative PCR evaluated POSTN, TGF-β1, and SNAI2 expression in 22 patients and 6 controls. Correlations with fecal calprotectin, the Pediatric Crohn's Disease Activity Index (PCDAI), and the Pediatric Ulcerative Colitis Activity Index (PUCAI) were determined. Results: Periostin, TGF-β, and SLUG expression were significantly increased in pIBD compared with controls. Periostin levels were higher in CD than in UC. All markers correlated positively at mRNA and protein levels. Notably, periostin showed an inverse correlation with fecal calprotectin and PCDAI scores. Conclusions: Periostin, TGF-β, and SLUG may represent biomarkers of pIBD activity. Periostin appears to mediate inflammation and promote mucosal fibrosis or repair, and its inverse association with disease activity suggests a potential therapeutic role in pIBD.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
09:31Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:16TGF - β Signaling Pathway
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...